These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7981446)

  • 1. Oral contraceptive use and the prognosis of breast cancer.
    Schönborn I; Nischan P; Ebeling K
    Breast Cancer Res Treat; 1994; 30(3):283-92. PubMed ID: 7981446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early oral contraceptive use as a prognostic factor in breast cancer.
    Olsson H; Möller TR; Ranstam J; Borg A; Fernö M
    Anticancer Res; 1988; 8(1):29-32. PubMed ID: 3358638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. German Breast Cancer Study Group.
    Sauerbrei W; Blettner M; Schmoor C; Bojar H; Schumacher M
    Eur J Cancer; 1998 Aug; 34(9):1348-51. PubMed ID: 9849415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does previous exposure to oral contraceptives modify survival in breast cancer?].
    Schönborn I; Ebeling K; Nischan P
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):559-63. PubMed ID: 8001752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
    Kay CR
    Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
    Pike MC; Henderson BE; Krailo MD; Duke A; Roy S
    Lancet; 1983 Oct; 2(8356):926-30. PubMed ID: 6138501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X
    NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer.
    Balslev I; Christensen IJ; Rasmussen BB; Larsen JK; Lykkesfeldt AE; Thorpe SM; Rose C; Briand P; Mouridsen HT
    Int J Cancer; 1994 Jan; 56(1):16-25. PubMed ID: 8262673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in breast cancer and age at start of oral contraceptive usage.
    Ranstam J; Olsson H; Garne JP; Aspegren K; Janzon L
    Anticancer Res; 1991; 11(6):2043-6. PubMed ID: 1776838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptive use has no adverse effect on the prognosis of breast cancer.
    Rosner D; Lane WW
    Cancer; 1986 Feb; 57(3):591-6. PubMed ID: 3942995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of oral contraceptives on the prognosis of breast cancer in young women.
    Rosner D; Lane WW; Perez Brett R
    Cancer; 1985 Apr; 55(7):1556-62. PubMed ID: 3978550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor.
    Saimura M; Fukutomi T; Tsuda H; Sato H; Miyamoto K; Akashi-Tanaka S; Nanasawa T
    J Surg Oncol; 1999 Jun; 71(2):101-5. PubMed ID: 10389866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.
    Schönborn I; Zschiesche W; Spitzer E; Minguillon C; Möhner M; Ebeling K; Grosse R
    Breast Cancer Res Treat; 1994; 29(3):287-95. PubMed ID: 7914107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Researchers can now investigate long-term effects of OCs on cancer.
    Rubin GL; Peterson HB
    Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.
    Chie WC; Li CY; Huang CS; Chang KJ; Yen ML; Lin RS
    Int J Cancer; 1998 Jul; 77(2):219-23. PubMed ID: 9650556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl-p-hydroxyphenyllactate-esterase activity in breast cancer: a potentially new prognostic factor in short-term follow-up.
    Carbone A; Serra FG; Ferrandina G; Scambia G; Terribile D; Bellantone R; Piantelli M; Ranelletti FO
    Cancer Res; 1997 Dec; 57(23):5406-9. PubMed ID: 9393767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.